The world’s first medication known to improve stroke recovery is based on traditional Chinese medicine (TCM), thanks to the approach of testing TCM in Western-style clinical trials.
NeuroAiD™, a stroke drug formulated from natural ingredients used in Chinese medicine, was developed to aid post-stroke recovery and has recently been approved for use in seven countries including Singapore.
At a recent standalone symposium in Seoul, Korea, Alzheimer’s researchers spoke about emerging treatment options for the early stages of this debilitating disease. Highlights from the symposium are:-
| Speaker | Presentation Title |
| Professor Florence Pasquier Professor of Neurology Head of Resources and Research Memory Centre University Hospital Lille, France |
Mild Cognitive Impairment - Early Stage of Alzheimer’s Disease |
| Helene-Mathiex Fortunet, MD Associate Professor Medical Affairs Director (Primary Care Products) IPSEN |
The Role of EGb761® in Cognitive Disorders & Pre-dementia in the Elderly |
| Professor Bruno Vellas, MD Chairman of EADC (European Alzheimer’s Disease Consortium) Chief of Department of Internal Medicine and Geriatrics Professor of Medicine, Univerisity Hospital Centre Toulouse, France |
The Role of EGb761® in Cognitive Disorders & Pre-dementia in the Elderly |
It has been a century since Alzheimer’s disease (AD) was first described in 1906, and it has become the most prevalent cause of dementia wroldwide. ...In Europe and the United States, various cerebra; and peripjeral vasotherapeutic agents - classified in Europe as C4A agents - are used to treat memory impairment in the elderly, and have the potential for preventing a decline in cognitive function. One of these agents is a special standardized Ginkgo biloba extract: EGb761®.... Recently, a number of studies have further explored this potential role of EGb761®.
